Rebamipide

CAS No.	90098-04-7	Cat. No.	BCP07230
Name	Rebamipide
Synonyms	Mucosta;OPC12759;Proamipide;Rebagen;OPC 12759;OPC-12759;
Formula	C19H15ClN2O4	M. Wt	370.79

Description	Rebamipide is the first anti-gastric ulcer and antigastritis drug that not only increases endogenous prostaglandin in gastric mucosa but also scavenges oxygen-derived free radicals and inhibits their production. The inhibitory effect of rebamipide on lipid peroxidation induced by a free radical initiator was also demonstrated by the in vitro system using rat gastric mucosal homogenates. These data indicate that rebamipide offers a potential for protection against reactive oxygen- and activated neutrophil-associated gastric mucosal injury by scavenging hydroxyl radical and inhibiting neutrophil activation or lipid peroxidation. Rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. Rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy . Rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse.
Pathways	GPCR/G Protein
Targets	Prostaglandin Receptor

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.